NEW YORK (GenomeWeb) – Life sciences informatics company Benchling said today that it has closed a $14.5 million Series B round of venture capital. Benchmark led the round, with participation from Fidelity Investments' F-Prime Capital and previous investor Thrive Capital.

As as result of the investment, Benchmark General Partner Eric Vishria is joining the board of San Francisco-based Benchling. He touted the rise of biologics as a major factor in backing Benchling.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.